Acute Coronary Syndrome Clinical Trials — A Patient's Guide

What is acute coronary syndrome?

Acute coronary syndrome (ACS) is an umbrella term for what happens when blood flow to part of the heart is suddenly blocked or severely reduced. It covers three closely related events:

• STEMI (ST-elevation myocardial infarction) — a heart attack where one of the main heart arteries is fully blocked. The blockage shows up as ST elevation on the ECG. STEMIs are usually treated emergently with cardiac catheterization and a stent (PCI), or sometimes clot-busting medication.
• NSTEMI (non-ST-elevation myocardial infarction) — a heart attack where the artery is partially blocked or briefly closed and then reopened. There is no ST elevation on the ECG, but a blood test (troponin) is elevated, confirming heart muscle injury.
• Unstable angina — chest pain or related symptoms at rest or with minimal effort, without a troponin elevation. Many cardiologists treat this similarly to NSTEMI because the underlying problem (an unstable plaque) is the same.

After the acute event, you enter what cardiologists call the secondary-prevention phase — the weeks and months after the heart attack when the focus shifts from saving heart muscle to preventing the next event. Most ACS clinical trials enroll during this secondary-prevention phase, typically somewhere from a few weeks to about 12 months after the index event, once you are clinically stable and on standard guideline-directed therapy.

If you do not know exactly which type of ACS you had, that is fine. Bring your hospital discharge summary, cath lab report, and a current medication list to screening — the team will sort it out with you.

What ACS trials are testing in 2026

Post-ACS research is unusually active right now. Current trials are exploring several directions at once:

• Antiplatelet medications. New oral antiplatelets, new combinations, and investigational antithrombotic strategies are being studied to see if they reduce repeat heart attacks and strokes after ACS without raising bleeding risk too much. Pivotal Phase 3 programs in this space include the LIBREXIA-ACS study (a novel antithrombotic strategy in patients following an ACS event).
• Lipid management beyond statins. Most ACS patients leave the hospital on a high-intensity statin, but many do not get LDL low enough. Trials are testing PCSK9 inhibitors, lipoprotein(a)-lowering agents, and other lipid pathways layered on top of statins.
• Anti-inflammatory therapy. Inflammation plays a role in plaque instability. Trials continue to explore targeted anti-inflammatory medications added to standard care.
• Cardiac protection during PCI. Investigational strategies aim to reduce heart muscle damage during and immediately after the cath-lab procedure.
• Heart failure prevention after a large MI. Patients with substantial heart muscle damage are at higher risk of developing heart failure later. Several trials test medications and devices intended to preserve pumping function in this group.
• Long-acting injectables replacing daily pills. A growing area: an injection every few weeks or months that replaces a daily pill (for example for lipid lowering or antithrombotic strategies), with the goal of better adherence after a stressful hospitalization.

A trial is not a guess. By the time a treatment reaches Phase 2 or Phase 3, it has already gone through earlier safety testing. The trial is asking a more specific question: does this work in real post-ACS patients on top of guideline-directed therapy, and is the risk reasonable for the potential benefit?

Who might be eligible

Every ACS trial has its own eligibility list. A few common requirements come up again and again:

• A documented ACS event. STEMI, NSTEMI, or unstable angina, confirmed by hospital records (discharge summary, ECG, troponin, cath lab report).
• Within a specific time window. Many trials enroll patients somewhere between roughly 6 weeks and 12 months after the index event. Some enroll earlier, some later. This window is fixed by the trial design.
• Standard PCI or medical management completed. If you needed a stent, it has been placed. If you were managed medically, that decision has been made and documented.
• On guideline-directed therapy. Typically a statin, an antiplatelet (often aspirin plus a P2Y12 inhibitor like ticagrelor, prasugrel, or clopidogrel), and a beta-blocker. Some trials also require an ACE inhibitor / ARB or a SGLT2 inhibitor depending on your other conditions.
• Clinically stable from the acute event. No ongoing chest pain, no recent hospitalization for cardiovascular instability, blood pressure and heart rate reasonably controlled.
• Lab values within trial-defined ranges. Kidney function, liver function, blood counts, and platelet count are commonly checked.
• Ability to commit. ACS trials usually involve regular follow-up over months to years.

You may be excluded for things like active bleeding, planned major surgery, very poor kidney function, certain other medications that interact with the investigational drug, or being enrolled in another investigational study. None of these are personal — they are study-design decisions made to keep results clear and participants safe.

The honest reality: most patients who screen for any one trial do not end up enrolling in that specific trial. If the time window or eligibility does not match, we check whether another open study fits.

What participation involves

ACS trials usually combine an investigational treatment (a new pill, injection, or combination) with structured cardiology follow-up. The structure varies by protocol, but a typical pattern looks like this.

Screening (1-3 hours)

You meet the trial team. The Principal Investigator reviews your history with you, including your hospital records from the ACS event. Screening usually includes:

• A focused medical history and review of your hospital discharge paperwork
• Vital signs (blood pressure, heart rate)
• An ECG
• A blood draw for kidney function, liver function, lipids, and platelets
• A possible echocardiogram (echo) if recent imaging is not available
• A full review of your current medications and any allergies, especially blood thinners and other antiplatelets

You go through informed consent: a detailed document explaining what the trial is studying, what is involved, the known risks (including bleeding risk if the investigational treatment is antithrombotic), and your right to leave at any time. (For a section-by-section walkthrough, see our consent-form reading guide.)

Baseline visit

If screening confirms eligibility, a baseline visit finalizes labs, confirms your medication list, randomizes you (if applicable), and starts the investigational treatment.

Treatment phase

The cadence depends on the trial. A common pattern:

• First year: clinic visits every 1-3 months, with vitals, focused exam, ECG when relevant, lab work, and a check on side effects and adherence.
• After the first year: visits every 3-6 months until the trial ends.

The investigational treatment may be a daily pill, a periodic injection, or a combination. You may be asked to keep a brief symptom diary or track any chest pain, shortness of breath, bleeding, or bruising between visits. Phone check-ins are common, especially in the first weeks after starting a new treatment.

End-of-study and trial-specific follow-up

At the end of the trial-defined treatment period, you have a final visit. Many ACS trials add a follow-up safety period after treatment stops. After all of that, you return to your regular cardiology team for ongoing care.

What you might gain

Patients have different reasons for considering an ACS trial. Common ones:

• Access to a treatment your cardiologist cannot currently prescribe — because it is still investigational and is not yet FDA-approved for routine use.
• Closer cardiology follow-up — more frequent visits, more frequent labs, and more touchpoints with the trial team than routine post-ACS care typically provides.
• Possible reduction in the risk of another cardiovascular event for some participants, depending on what the trial finds.
• A meaningful contribution to research that may help future patients after a heart attack.

We want to be honest here: an investigational treatment may help you, may not change your outcome, or in some cases may have side effects. No one — not your cardiologist, not the trial team, not the sponsor — can promise benefit. That is exactly why the trial is being done: to find out.

What the risks are

Risks in ACS trials are spelled out in detail in the consent form. The most common categories:

• Side effects of the investigational treatment. Each drug or combination has its own profile. The consent form lists known and possible side effects.
• Bleeding risk. Many ACS trials test antiplatelet or anticoagulant strategies, sometimes layered on top of the antiplatelets you are already taking. That can mean a higher risk of bruising, nosebleeds, gastrointestinal bleeding, or — less commonly — more serious bleeding. The consent form quantifies this risk based on prior data.
• Randomization to a control treatment. Many trials are designed so some participants receive the investigational treatment and some receive standard care or placebo on top of standard care. You may not get the investigational treatment.
• Time commitment. Visits, labs, and check-ins take time and energy.
• Recurrent cardiovascular events. Patients with prior ACS are at higher baseline risk for another event, regardless of the trial. Trial follow-up monitors closely for recurrent events. ACS trials run intensive safety monitoring through an independent Data Safety Monitoring Board (DSMB) that reviews accumulating data and can pause or modify a trial if a safety signal appears.

You can withdraw at any time, for any reason, without it affecting your future medical care.

How to find out if you are eligible

There are three easy ways to start the conversation:

• Call (786) 703-5941. A 15-minute eligibility screening is free and does not commit you to anything.
• Use our patient contact form at /contact-patient.
• Have your cardiologist or primary care doctor refer you. We coordinate with most Miami-area cardiology practices.

When you call, please be ready to share: the date of your ACS event (or roughly the month and year), the type if you know it (STEMI, NSTEMI, or unstable angina), whether you had a stent, and your current medications — especially antiplatelets, anticoagulants, statins, and beta-blockers. Hospital discharge paperwork is the single most useful document to have on hand.

Active ACS trials at Amavita Research

We currently have ACS protocols open at Amavita Research. As of the date on this page, an active study is:

• LIBREXIA-ACS — a Phase 3 study (Janssen 70033093ACS3003, NCT05754957) evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event. See /trials/librexia-acs for details.

For the current list of trials and contact information, see /therapeutic-areas/acute-coronary-syndrome. Trial availability changes — call us for the most current status.

Questions worth asking before you join

The trial team welcomes these questions. If yours is not on the list, ask anyway.

• Does my ACS event date fall inside the trial's time window? This is one of the first things screening checks.
• What is the chance I will receive the investigational treatment versus placebo or standard care? This is set by the trial design and the team can tell you.
• How does the investigational treatment interact with my current antiplatelet or anticoagulant? Important for any new antithrombotic study layered on aspirin, ticagrelor, prasugrel, clopidogrel, or an oral anticoagulant.
• What is the bleeding risk profile of this study, based on prior data? The consent form has the numbers.
• How will my regular cardiologist be kept in the loop? With your permission, we send updates and study data to your cardiologist so your care stays coordinated.
• What happens if I have another cardiac event during the study? The trial team and your cardiologist coordinate on acute care; the trial protocol defines how the event is documented and how the investigational treatment is handled.
• Does my specific ACS history (STEMI vs NSTEMI vs unstable angina, prior heart attacks, prior stents) actually fit this trial? The PI will be honest if your history is not a match.

---

About the author: Amavita Research is a cardiovascular clinical trial site embedded inside amavita Heart and Vascular Health® in North Miami Beach, FL. Our ACS trials are led by interventional cardiologist Dr. Pedro Martinez-Clark, MD, FACC, with 24/7 cath-lab access via the affiliated Advanced Cardiovascular of Miami ambulatory surgical center and a long track record as a principal investigator on post-ACS antithrombotic and lipid-lowering studies. We see patients in English, Spanish, Haitian Creole, and Brazilian Portuguese. Call (786) 703-5941 or visit /contact-patient.